Dare Bioscience, Inc. (DARE): Submission of Matters to a Vote of Security Holders

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. A special meeting of stockholders (the “Meeting”) of Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) was held on November 10, 2026 and the following proposals were voted upon by our stockholders. The proposals ar

Event · Shareholder vote
Original reporting
Published Nov 12, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$DARE
Neutral
medium confidence
Mentioned
$DARE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DARENeutralLow
01

Why it matters

The filing provides transparency on governance matters but does not alter the company's financial outlook or operational plans.

02

Market read

Limited relevance; the disclosure is a standard proxy vote with no immediate market‑moving implications.

03

What to watch

Potential future dilution from warrant exercises is noted, but the immediate impact is minimal.

Relevance 6/10Novelty 2/10Timing: post‑filing today

Background

Dare Bioscience filed an 8‑K detailing shareholder approval of a proposal to issue shares upon warrant exercise and an adjournment to solicit additional proxies, both routine items under Nasdaq rules.

Company-level read

Ticker impact

$DARENeutralMedium confidence
Context

SEC 8‑K reports the results of a shareholder vote on warrant‑exercise shares and a proxy adjournment, providing the first public disclosure of the vote counts.

Expected impact

no significant impact as the market has likely priced the outcome already

Evidence & confidence

The filing is a standard proxy disclosure; such votes rarely move the stock unless a major amendment is approved, which is not the case here.

Market effects

none

none

none

Counterpoint

If the vote had revealed unexpected dissent, it could signal governance risk, but the results show strong approval.

Key entities

  • Dare Bioscience, Inc.

    Biotech firm listed on Nasdaq under ticker DARE.

Related articles

$DAREMed

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.